Rosuvastatin (AZD4522) + Placebo
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thrombosis
Conditions
Venous Thrombosis, Pulmonary Embolism
Trial Timeline
Feb 1, 2011 → Mar 1, 2013
NCT ID
NCT01164540About Rosuvastatin (AZD4522) + Placebo
Rosuvastatin (AZD4522) + Placebo is a phase 3 stage product being developed by AstraZeneca for Venous Thrombosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01164540. Target conditions include Venous Thrombosis, Pulmonary Embolism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01164540 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Venous Thrombosis